Table 3
Mean difference (95% CI) for all secondary outcome measures between the group receiving added salmeterol and the group receiving increased dose of ICS
| Outcome measure | Difference in original units† | Inconsistency measures | |
|---|---|---|---|
| Fixed effects | Random effects | ||
| †Mean difference represents the mean outcome measure for the group receiving added salmeterol minus the mean outcome measure for the group receiving increased dose of inhaled corticosteroid. | |||
| Morning PEF (l/min) | 23 (19 to 28) | 23 (15 to 30) | 63.7 (25.5 to 82.3) |
| Evening PEF (l/min) | 19 (15 to 23) | 19 (13 to 24) | 29.9 (0.00 to 82.3) |
| FEV1 (l) | 0.12 (0.09 to 0.15) | 0.12 (0.06 to 0.18) | 71.0 (36.7 to 86.7) |
| Night awakenings (no/week) | −0.03 (0.00 to −0.07) | −0.03 (0.01 to −0.07) | 20.5 (0.00 to 65.1) |
| Day time β agonist use (puffs/day) | −0.58 (−0.44 to −0.72) | −0.60 (−0.35 to −0.84) | 70.3 (30.5 to 87.3) |
| Night time β agonist use (puffs/night) | −0.08 (−0.02 to −0.13) | −0.08 (−0.00 to −0.16) | 58.0 (0.00 to 83.0) |
